EW · Edwards Lifesciences Corp
Price
Snapshot
50 fields · last close| Market Cap | $49.08B |
| P/E | 48.84 |
| Float | 573.4M |
| Beta | 0.84 |
| Volatility | 20.9% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 84.3 |
| Price | 85.15 |
| Change | +0.00% |
| Prev Close | 85.15 |
| Open | 85.52 |
| Day Low | 84.66 |
| Day High | 86.48 |
| Avg Vol | 3 |
| Avg $ Vol | $297.8M |
| 52W High | 96.29 |
| 52W Low | 72.30 |
| 52W Pos | 53.6% |
| From High | −11.57% |
| From Low | +17.77% |
| Max DD 1Y | −13.19% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.04% |
| SMA 50 | −3.76% |
| SMA 200 | +0.02% |
| RSI (14) | 40.5 |
| Vol 30D | 22.7% |
| Vol 90D | 23.7% |
| 1Y Range | 72–96 |
| Daily bars | 526 |
| Perf Week | −1.32% |
| Perf Month | −6.24% |
| Perf Quarter | −10.54% |
| Perf Half Y | +5.06% |
| Perf Year | +11.58% |
| Perf YTD | −0.21% |
| Prev Day | +0.00% |
| Clavix | A- |
| Debt / Eq | 0.06 |
| Curr Ratio | 3.72 |
| Int Cover | 110.0× |
| FCF Margin | 22.0% |
| Rev Growth | +11.6% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 3 / 49 |
What EW does
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Clavix risk grade
regraded every trading dayEW grades A-, 84.3 of 100. Steadiest on Macro Resilience (71), most exposed on News Sentiment (62, mixed). 4 of the 4 weighted dimensions sit above the Health Care median. Ranks 3 of 49 in Health Care by Clavix score.
How rough the ride is
| EW | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.84 | 0.85 |
| Volatilityannualized | 20.9% | 21.3% |
| Max drawdown, past yearworst peak-to-trough fall | −13.2% | — |
| Typical daily movemedian absolute daily change | 0.87% | — |
| Days beyond ±3%of the last 252 sessions | 18 (7%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| EW | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.84 | 0.85 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| EW | |
|---|---|
| 1 week | −1.3% |
| 1 month | −6.2% |
| Year to date | −0.2% |
| 1 year | +11.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| EW | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Jul |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 5 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| EW | |
|---|---|
| Revenue growthyear over year | +11.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for children born with heart defects who need a pulmonary valve replacement.
The FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, a surgical pulmonary valve made specifically for children with congenital heart disease who need a pulmonary valve replacement. It is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy.
An analyst firm called Wall Street Zen downgraded its rating on Edwards Lifesciences (EW) from 'buy' to 'hold' in a research note on Saturday. No further information was provided.
Edwards Lifesciences outlined its structural heart growth strategy, highlighting updated Medicare coverage that could enable 100-200 additional U.S. centers to perform TAVR (a minimally invasive procedure to replace a diseased heart valve without open-heart surgery), and a goal to build a multibillion-dollar transcatheter mitral and tricuspid valve business by 2030 using its PASCAL, EVOQUE, and Sapien M3 technologies.
An analysis piece looking at whether Edwards Lifesciences' stock price of $88.25 is reasonable, noting the shares are up 18.4% over the past year but still down 27.1% over five years, with fresh policy news around its core heart valve business following a Medicare expansion of TAVR coverage.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BDX | Becton Dickinson and Co | A- | $48.16B | 51.12 | 0.24 | Compare |
| MDLN | Medline Inc | B | $46.82B | 67.56 | 0.95 | Compare |
| HUM | Humana Inc | B | $46.63B | 36.46 | 0.67 | Compare |
| CAH | Cardinal Health Inc | A- | $52.86B | 30.84 | 0.55 | Compare |
| VEEV | Veeva Systems Inc | B- | $44.25B | 43.61 | 0.89 | Compare |
| COR | Cencora Inc | B+ | $58.98B | 22.47 | 0.59 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $40.84B | 35.83 | 1.56 | Compare |
| BSX | Boston Scientific Corp | B | $61.74B | 16.80 | 0.59 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.